Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective

Published:2024-04-04 Issue:1 Volume:27 Page:543-553
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Brodtkorb Thor-Henrik¹^ORCID,Knight Christopher²,Kamgar Farzam¹,Teitsson Siguroli³^ORCID,Kurt Murat⁴,Patel Miraj Y.⁴^ORCID,Poretta Tayla⁴,Mamtani Ronac⁵,Palmer Stephen⁶^ORCID

Affiliation:

1. RTI Health Solutions, Ljungskile, Sweden

2. RTI Health Solutions, Manchester, UK

3. Bristol Myers Squibb, Uxbridge, UK

4. Bristol Myers Squibb, Princeton, NJ, USA

5. Division of Hematology - Oncology, University of Pennsylvania, Philadelphia, PA, USA

6. Centre for Health Economics, University of York, York, UK

Funder

Bristol Myers Squibb

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2329019

Reference36 articles.

1. Cancer statistics, 2022

2. The burden of bladder cancer care

3. The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis

4. Epidemiology of Bladder Cancer

5. NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines) for bladder cancer. National Comprehensive Cancer Network; V.1; 2020. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction;Journal of Medical Economics;2024-06-07

2. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo;Journal of Medical Economics;2024-03-25